# Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects

> **NCT02463045** · PHASE1 · COMPLETED · sponsor: **Topivert Pharma Ltd** · enrollment: 67 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** TOP1288

## Key facts

- **NCT ID:** NCT02463045
- **Lead sponsor:** Topivert Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02463045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02463045, "Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02463045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*